Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics (Nasdaq: VYGR), as the companies yesterday announced a restructuring of their gene therapy relationship.
Under the terms of the agreement, Voyager re-gains worldwide rights to the VY-HTT01 Huntington’s disease program and ex-US rights to the VY-FXN01 Friedreich’s ataxia program. The ex-US rights to VY-FXN01 are, in turn, transferred from Voyager to Neurocrine Biosciences (Nasdaq: NBIX) under the terms of the collaboration agreement between Voyager and Neurocrine Biosciences announced in January 2019.
Despite the mixed news, Voyager’s shares, which fell 3.4% pre-market, ended trading on Monday up 10.35% at $26.75. Sanofi was up 2.7% at 77.52 euros by late afternoon today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze